Abstract: Initially utilized in the treatment of myelofibrosis and rheumatoid arthritis, JAK inhibitor's indications were gradually expanded to dermatology. Up until now, JAK inhibitor has been approved for the treatment of psoriasis, alopecia areata, atopic dermatitis, graft-versus-host disease and other skin diseases in China. In fact, more and more autoimmune and inflammatory skin diseases have shown favorable response to JAK inhibitors in clinical studies. We summarized the current clinical research of JAK inhibitors' off-label prescriptions in dermatology, aiming to provide references for clinicians.

Key words: JAK inhibitor, off-label prescription, JAK-STAT signaling pathway